Derm Fall Clinical

Skin clearance and route of administration drove treatment choices among 202 patients with psoriasis in the ENCOMPASS-PP discrete choice experiment.

Oral prifemilast, a PDE4B-selective inhibitor, led to PASI 75 attainment in up to 57.4% of those with psoriasis at week 16 vs 10.8% with placebo.

KT-621, an oral STAT6 degrader, cut mean EASI by 62.6% after 4 weeks with no treatment-related adverse events in a phase 1b atopic dermatitis study.

Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.

Aaron Farberg, MD, discusses gene expression testing in atopic dermatitis and melanoma, Ameluz PDT for basal cell carcinoma, and the psoriasis pipeline.

Jennifer Hsiao, MD, shares how she sets expectations, selects and reassesses biologics, and screens for comorbidities in patients with hidradenitis suppurativa.

This segment of Nguyen's 2026 Fall Clinical Dermatology interview highlights key insights on early dermatology career strategies and other information.

This Q&A interview segment with Harrison Nguyen, MD, MBA, MPH, highlights key points made during his 2026 Fall Clinical Dermatology meeting sessions.

Sarina Berger Elmariah, MD, PhD, MPH, reviews 3-year nemolizumab data showing deeper skin clearance and lasting itch relief in atopic dermatitis responders.

Todd Schlesinger, MD, reviews new photodynamic and adjuvant immunotherapy options for keratinocyte carcinoma, plus pipeline therapies and exosome research.

Todd Schlesinger, MD, discusses Ameluz PDT for sBCC, adjuvant cemiplimab, remibrutinib for symptomatic dermographism, and nonsurgical skin cancer care.

Sarina Berger Elmariah, MD, PhD, MPH, discusses 3-year nemolizumab data in early responders and what IL-31 blockade means for itch and atopic dermatitis.

At Fall Clinical 2026, Aaron S. Farberg, MD, shares how gene expression testing guides melanoma and atopic dermatitis care and what Ameluz PDT adds.

Catch up on HCPLive’s second-half Fall Clinical 2026 coverage, from HS underdiagnosis in men and long-term acne data to advanced cutaneous SCC care.

US claims data from Fall Clinical 2026 suggest hidradenitis suppurativa symptoms occur at similar rates in both sexes, hinting at underdiagnosis in males.

Raj Chovatiya, MD, PhD, explains how to approach biologic selection in atopic dermatitis and previews oral, multispecific, and novel-target therapies.

Jennifer Hsiao, MD, discusses HS treatment expectations, biologic selection, oral JAK inhibitors, and comorbidity screening.

Phase 3 extension shows oral denifanstat sustains acne lesion reductions through 52 weeks, with 57% IGA success and 77% fewer inflammatory lesions.

Shannon C. Trotter, DO, FAOCD, discusses immunotherapy in advanced cutaneous squamous cell carcinoma and why dermatologists should stay involved.

Raj Chovatiya, MD, PhD, discusses biologic choice in atopic dermatitis, pipeline strategies, and remibrutinib’s approval for symptomatic dermographism.

In this interview, Iltefat Hamzavi, MD, explains why early advanced therapy in hidradenitis suppurativa matters beyond pivotal trial primary endpoints.

Iltefat Hamzavi, MD, outlines how symptom questionnaires, comorbidity screening, wound care, and procedures shape hidradenitis suppurativa care.

Catch up on HCPLive’s first-half Fall Clinical 2026 coverage, including new psoriasis and atopic dermatitis data and expert insights on HS and vitiligo.

New ARCADIA and OLYMPIA LTE data show nemolizumab sustained skin clearance and itch relief for up to 3 years in atopic dermatitis and prurigo nodularis.

Two-year ICONIC-LEAD data show oral icotrokinra sustained PASI 90 and IGA 0/1 responses in more than 70% of adults and adolescents with plaque psoriasis.

New TOGETHER-PsO data show ixekizumab plus tirzepatide drove broader immune and metabolic biomarker changes than ixekizumab alone in psoriasis and obesity.

Iltefat Hamzavi, MD, explains how topical and oral JAK inhibitors fit into vitiligo care and which patients are the best candidates for each approach.

In this session, Cheri Frey, MD, shared a framework for evaluating skincare products, from ingredient plausibility to clinically meaningful results.

Andrea Murina, MD, reviewed strategies for optimizing HS biologics, combining therapies, and reconsidering the role of surgery.

HCPLive previews Fall Clinical 2026 in Las Vegas, October 8-11, with key sessions on atopic dermatitis, psoriasis, and vitiligo, plus expert interviews.